Adamas announces fda approval for second indication for gocovri® as an adjunctive treatment to levodopa/carbidopa in parkinson's disease patients experiencing off episodes

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the u.s. food and drug administration (fda) for a supplemental new drug application for gocovri® (amantadine) extended release capsules, gaining a second indication for the product. gocovri is now approved as an adjunc
ADMS Ratings Summary
ADMS Quant Ranking